Loading clinical trials...
Loading clinical trials...
Phase II, Single-arm Study of Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Treated With Neoadjuvant Concurrent Chemoradiotherapy Followed by Curative Resection
Conditions
Interventions
Pembrolizumab
Curative resection
+3 more
Locations
1
South Korea
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, South Korea
Start Date
February 14, 2017
Primary Completion Date
May 13, 2021
Completion Date
August 13, 2021
Last Updated
February 15, 2017
NCT01629498
NCT02495896
NCT04062708
NCT01993810
NCT01737502
NCT03154190
Lead Sponsor
Samsung Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions